4//SEC Filing
ESHELMAN FREDRIC N 4
Accession 0001437749-22-008178
CIK 0001513818other
Filed
Apr 3, 8:00 PM ET
Accepted
Apr 4, 4:17 PM ET
Size
10.4 KB
Accession
0001437749-22-008178
Insider Transaction Report
Form 4
Aravive, Inc.ARAV
ESHELMAN FREDRIC N
Director
Transactions
- Exercise/Conversion
Common Stock
2022-04-01$0.00/sh+4,545,455$455→ 9,211,769 total(indirect: See footnote) - Exercise/Conversion
Pre-Funded Warrant (right to buy)
2022-04-01+4,545,455→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (4,545,455 underlying)
Transactions
- Exercise/Conversion
Common Stock
2022-04-01$0.00/sh+4,545,455$455→ 9,211,769 total(indirect: See footnote) - Exercise/Conversion
Pre-Funded Warrant (right to buy)
2022-04-01+4,545,455→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (4,545,455 underlying)
Footnotes (3)
- [F1]The shares of common stock of Aravive, Inc. (the "Company") are owned, and the exercised pre-funded warrants were owned, directly by Eshelman Ventures, LLC, an entity wholly owned by the Reporting Person. The Reporting Person, Dr. Fredric Eshelman, who is the Executive Chairman of the Company's Board of Directors, disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F2]The Pre-Funded Warrant expires when it is fully exercised and is exercisable immediately. Notwithstanding the foregoing, the Pre-Funded Warrant was not exercisable until the Company obtained the Requisite Stockholder Approval (as defined below) and no shares issuable upon exercise of the Pre-Funded Warrant were to be issued or delivered upon any proposed exercise of the Pre-Funded Warrant, and the Pre-Funded Warrant was not exercisable to the extent that such issuance, delivery, exercise or exercisability would result in Eshelman Ventures, LLC or a "person" or "group" (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended) beneficially owning in excess of 19.99% of the then-outstanding shares of the Company's common stock. (continued to footnote 3)
- [F3]"Requisite Stockholder Approval" means the stockholder approval contemplated by Rule 5635 of the Nasdaq Stock Market listing rules with respect to the issuance of the shares of the Company's common stock issuable upon exercise of the Pre-Funded Warrant in excess of the limitations imposed by such rule. Requisite Stockholder Approval was obtained on April 1, 2022 at a Special Meeting of the Company and Eshelman Ventures proceeded to exercise the Pre-Funded Warrant in full on such date.
Documents
Issuer
Aravive, Inc.
CIK 0001513818
Entity typeother
Related Parties
1- filerCIK 0001033409
Filing Metadata
- Form type
- 4
- Filed
- Apr 3, 8:00 PM ET
- Accepted
- Apr 4, 4:17 PM ET
- Size
- 10.4 KB